Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biosense Webster, Inc.
Biosense Webster to Support Landmark Clinical Trial of Atrial Fibrillation
July 4th, 2009
Biosense Webster, Inc., a leader in the diagnosis and treatment of cardiac arrhythmias, will be part of a public/private collaboration to fund a global clinical trial to compare catheter ablation to medical therapy in treating atrial fibrillation. AFib, as it is more commonly referred to, is the most prevalent cardiac arrhythmia (heart rhythm disorder), affecting an estimated 20 million people worldwide. It is also one of the most common causes of stroke. Biosense Webster joins the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health, and another medical device company to fund the CABANA trial (Catheter Ablation Versus...
Source: Law & Health Weekly (2009-07-04)
|
